A view from the Center

Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

What to watch for in 2017: Startups, entrepreneurs, and innovations

by Doug Beaudoin, Principal, Deloitte Consulting LLP

Every year Forbes holds a 30 under 30 in health care competition to highlight 30 young people who are founding companies, searching for treatments, and working to fix health policy. Headlining the list this year is 29-year-old Michael Martin, who after getting mugged, was inspired to come up with a smarter, more efficient way to alert emergency responders.

Read more

Collaboration as a key to success in pharmaceutical R&D

by Greg Reh, Principal, US and Global Life Sciences Leader, Delotite Consulting LLP

Biopharmaceutical companies are increasingly partnering with other health care stakeholders to address scientific and technological challenges, create greater efficiencies in research and development (R&D), and accelerate the development and delivery of new treatments for patients.

In fact, approximately 9,000 new biopharma R&D partnerships were formed between 2005 and 2014 at an annual growth rate of four percent during that ten-year period.1 Many of these partnerships have been focused on fueling scientific discovery.

Read more

12 medical technology innovations likely to transform health care in 2017

by Karen Taylor, Research Director, UK Centre for Health Solutions, Deloitte Services LP

2016 saw an increase in the adoption of medical technology innovations aimed at tackling some of the most intractable health care challenges. This blog shares some of the top innovations that we believe will have the greatest impact on the continued transformation of health care.

1. 3D printing is poised to make a big impact in 2017 – and is expected to be worth $1.2 billion by 2020.

Read more

Parkinson’s disease researchers shed light into the mysteries of the microbiome

by Doug Beaudoin, Principal, Deloitte Consulting LLP

Researchers at the California Institute of Technology have discovered a possible link between gut bacteria in patients with Parkinson’s disease and deterioration of motor skills. A diverse community of beneficial and sometimes harmful bacteria live in the gut and influence the functioning of the immune and nervous systems. The microbiome is communities of microorganisms, including bacteria,

Read more

Navigating new uncertainties in the health plan marketplace in 2017

by Greg Scott, Vice Chairman, US Health Plans Sector Leader, Deloitte Consulting LLP

We anticipate dramatic government-driven change (once again) in our industry in 2017. The new Administration and the 115th Congress have clear intent and many opportunities to fulfill their commitment to repeal and replace the Affordable Care Act (ACA). From any angle—political, legislative, budgetary, actuarial, administrative—ACA repeal and replacement options are fraught with complexity and challenges.

Read more

Considering the fate of the ACA: Repeal & devolve, not repeal & replace?

by Greg Scott, Vice Chairman, US Health Plans Sector Leader, Deloitte Consulting LLP

In the wake of what so many have called an “historic election,” I’m refreshing (or at least dusting off) my understanding of US political history. Beyond improving my own erudition, I’m trying to help our clients and our professionals consider how overarching political developments and historical trends might shape strategies and efforts to repeal and replace the Affordable Care Act (ACA).

Read more